AngioDynamics ANGO Med Tech — Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AngioDynamics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: AngioDynamics’s 10-Q, filed April 2, 2026, on SEC EDGAR. View the filing →
Ask your AI about AngioDynamics's med tech — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AngioDynamics's med tech — net sales?
- AngioDynamics (ANGO) reported med tech — net sales of $37.28M in Q4 2025.
- How has AngioDynamics's med tech — net sales changed year-over-year?
- AngioDynamics's med tech — net sales increased by 19.0% year-over-year, from $31.34M to $37.28M.
- What is the long-term trend for AngioDynamics's med tech — net sales?
- Over 4 years (2021 to 2025), AngioDynamics's med tech — net sales has grown at a 22.8% compound annual growth rate (CAGR), from $55.73M to $126.65M.
- What does med tech — net sales mean?
- Net sales for the Med Tech segment reflect the total revenue generated from the sale of medical, surgical, and diagnostic devices after accounting for returns, allowances, and discounts. This metric is the primary measure of the segment's market demand and top-line growth trajectory. It provides insight into the company's ability to capture market share within its specialized healthcare product categories.